{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:58Z","timestamp":1761871018679,"version":"build-2065373602"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Clin Inform"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rare B-rapidly accelerated fibrosarcoma gene (BRAF) mutations in advanced melanoma, and other malignancies, represent a significant clinical challenge due to sparse evidence on the efficiency of targeted therapy. Conventional genomic databases do not integrate detailed outcome data on treatments for patients with these mutations, requiring innovative informatics approaches.<\/jats:p>\n                  <jats:p>For the use case of patients with rare BRAF-mutated melanoma, we developed a \u201cTreatment Outcome Tool\u201d as a web-based database on rare cancers that aggregates anonymized, expert-validated clinical data. Unstructured interviews with dermato-oncologic experts guided the design, ensuring that the system allows users to query specific or combined rare BRAF mutations and retrieve key outcome measures, such as progression-free survival, overall response rate, and disease control rate with BRAF and\/or mitogen-activated proteinkinase kinase (MEK) inhibition. Data are collected via a structured input form. After rigorous review and quality assurance by dedicated experts, data are then transferred to an externally accessible R\/Shiny platform, where they can be assessed. The usability of the developed database was then evaluated by the System Usability Scale (SUS) of contributing dermato-oncologic experts.<\/jats:p>\n                  <jats:p>The first productive database version was implemented in October 2024. As of May 2025, the database contained data from 130 patients with 23 BRAF mutations. Evaluation of the \u201cTreatment Outcome Tool\u201d by 14 international dermato-oncologic experts yielded a median SUS score of 92.5, confirming excellent usability.<\/jats:p>\n                  <jats:p>Our database fills a critical gap in personalized oncology therapy by directly correlating rare BRAF mutation profiles with treatment outcomes. Our tool had usability and was found to be of high clinical value. The generic informatics framework chosen by us has the potential to be expanded to other rare tumors, ultimately enhancing evidence-based clinical practice and fostering international collaboration in cancer research.<\/jats:p>","DOI":"10.1055\/a-2717-3119","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:22Z","timestamp":1761870562000},"page":"1541-1549","source":"Crossref","is-referenced-by-count":0,"title":["Development and Evaluation of a Web-Based Outcome Database for Advanced Melanoma with Rare BRAF Mutations"],"prefix":"10.1055","volume":"16","author":[{"given":"Susanne","family":"Dugas-Breit","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University, Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Menzer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University, Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[{"name":"Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, Australia"},{"name":"Department of Medical Oncology Blacktown and Westmead Hospitals, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Clinical Informatics Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University, Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dugas","sequence":"additional","affiliation":[{"name":"Institute of Medical Informatics, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"03","key":"ref1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"D Schadendorf","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"J A Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"A Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1006\/scbi.1998.0113","article-title":"On the origin of multiple mutations in human cancers","volume":"8","author":"A L Jackson","year":"1998","journal-title":"Semin Cancer Biol"},{"issue":"6892","key":"ref7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"H Davies","year":"2002","journal-title":"Nature"},{"issue":"26","key":"ref8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"P B Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.pathol.2018.08.004","article-title":"Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases","volume":"50","author":"J Leichsenring","year":"2018","journal-title":"Pathology"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"A M Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/bjc.2013.143","article-title":"Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice","volume":"108","author":"L Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/jid.2014.366","article-title":"Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma","volume":"135","author":"A E Siroy","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"33","key":"ref13","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted therapy in advanced melanoma with rare BRAF mutations","volume":"37","author":"C Menzer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bjd.15436","article-title":"Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients","volume":"177","author":"G Richtig","year":"2017","journal-title":"Br J Dermatol"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11864-022-00946-4","article-title":"Targeted therapy for melanomas without BRAF V600 mutations","volume":"23","author":"C Menzer","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.21873\/cgp.20250","article-title":"Comparison of open-access databases for clinical variant interpretation in cancer: a case study of MDS\/AML","volume":"18","author":"H Banck","year":"2021","journal-title":"Cancer Genomics Proteomics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Z Sondka","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"M J Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"ref19","first-page":"A68","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge","volume":"19","author":"K Tomczak","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/CCI.21.00084","article-title":"My cancer genome: coevolution of precision oncology and a molecular oncology knowledgebase","volume":"5","author":"M E Holt","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"e29176","DOI":"10.2196\/29176","article-title":"An open-source, standard-compliant, and mobile electronic data capture system for medical research (OpenEDC): design and evaluation study","volume":"9","author":"L Greulich","year":"2021","journal-title":"JMIR Med Inform"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5582\/ddt.2022.01072","article-title":"A Japanese case of melanoma of unknown origin with a rare BRAFV600R mutation was successfully treated with BRAF\/MEK inhibitors","volume":"16","author":"H Kuriyama","year":"2022","journal-title":"Drug Discov Ther"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0000000000000376","article-title":"Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE","volume":"27","author":"A Rogiers","year":"2017","journal-title":"Melanoma Res"},{"issue":"23","key":"ref25","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"I de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3332\/ecancer.2018.886","article-title":"ReDO_DB: the repurposing drugs in oncology database","volume":"12","author":"P Pantziarka","year":"2018","journal-title":"Ecancermedicalscience"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12859-016-1065-y","article-title":"DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing","volume":"17","author":"N T Issa","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40246-016-0061-7","article-title":"The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies","volume":"10","author":"S E Patterson","year":"2016","journal-title":"Hum Genomics"}],"container-title":["Applied Clinical Informatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2717-3119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:32Z","timestamp":1761870572000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2717-3119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2717-3119","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1869-0327"],"issn-type":[{"value":"1869-0327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}